shutterstock_123182704

Horizon and Fulcrum Therapeutics form CRISPR collaboration

pharmafile | September 6, 2016 | News story | Manufacturing and Production, Research and Development Horizon Discovery, crispr, fulcrum, fulcrum therapeutics, gene editing, horizon, rare diseases 

Horizon Discovery has announced that it has entered into a partnership with Fulcrum Therapeutics to utilise Horizon’s CRISPR-based screening platform to identify novel targets for regulating gene expression in genetic diseases for which no effective treatments currently exist.

Fulcrum are a US-based firm founded as recently as July 2016 and have chosen Horizon as their preferred CRISPR-based screening platform provider to work on their projects going forward. The partnership is expected to run for between five and seven months.

Horizon will also use its expertise is bioinformatics and cell line libraries to identify novel gene regulation targets for further exploration by Fulcrum, in their attempt to develop next-generation therapies.

Advertisement

Dr Darrin Disley, CEO at Horizon, says: “CRISPR-based screening promises to be a powerful tool for the identification of novel targets and the collaboration with Fulcrum demonstrates the potential for this technology to be used in areas outside of oncology.”

Robert Gould, President and CEO at Fulcrum, comments: “It was natural for Fulcrum to turn to Horizon as a long-term partner. With their deep scientific expertise, and with a broad IP portfolio underpinning their work, we are confident in a productive and exciting collaboration.”

Sean Murray

Related Content

Rare diseases – spinal muscular atrophy

Spinal muscular atrophy (SMA) is a rare disease characterised by voluntary muscle weakness that can …

trial

Biogen and Stoke report positive results for Dravet syndrome drug

Biogen and Stoke Therapeutics have shared encouraging new data for their experimental treatment, zorevunersen, which …

Gene Weaver awarded Gates Foundation grant for programmable gene insertion platform

UK-based biotech Gene Weaver has received $515,000 from the Bill and Melinda Gates Foundation to advance …

The Gateway to Local Adoption Series

Latest content